US20060021616A1 - Inhaler - Google Patents
Inhaler Download PDFInfo
- Publication number
- US20060021616A1 US20060021616A1 US11/144,941 US14494105A US2006021616A1 US 20060021616 A1 US20060021616 A1 US 20060021616A1 US 14494105 A US14494105 A US 14494105A US 2006021616 A1 US2006021616 A1 US 2006021616A1
- Authority
- US
- United States
- Prior art keywords
- dose
- slide
- dry powder
- container
- inhaler device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000843 powder Substances 0.000 claims abstract description 66
- 239000003814 drug Substances 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 15
- 229940112141 dry powder inhaler Drugs 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims description 20
- 230000001419 dependent effect Effects 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 1
- 239000011888 foil Substances 0.000 abstract description 24
- 238000007789 sealing Methods 0.000 abstract description 5
- 230000004888 barrier function Effects 0.000 description 22
- 239000000463 material Substances 0.000 description 14
- 229910052782 aluminium Inorganic materials 0.000 description 10
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000010419 fine particle Substances 0.000 description 7
- 230000009471 action Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 4
- 238000010008 shearing Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000012387 aerosolization Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 2
- 229940110309 tiotropium Drugs 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000012545 Psychophysiologic disease Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012611 container material Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000005520 electrodynamics Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000004920 heat-sealing lacquer Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229920002493 poly(chlorotrifluoroethylene) Polymers 0.000 description 1
- 239000005023 polychlorotrifluoroethylene (PCTFE) polymer Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Chemical class [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0091—Inhalators mechanically breath-triggered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0066—Inhalators with dosage or measuring devices with means for varying the dose size
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/0081—Locking means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Definitions
- the present invention relates to a dry powder inhaler device for metered dry powder medicament doses, and particularly to a single dose inhaler.
- the inhaler is one relying on a user providing a necessary action/force in order to deliver a selected dose made available in the inhaler.
- the dosing of drugs is carried out in a number of different ways in the medical service today.
- Within health care there is a rapidly growing interest in the possibility of administering medication drugs as a powder directly to the airways and lungs of a patient by means of an inhaler in order to obtain an effective, quick and user-friendly delivery of such substances.
- the efficacy of inhaled doses often are much higher than e.g. orally administered capsules, the inhalation doses need only be a fraction of the medicament powder mass in an oral capsule.
- RSD relative standard deviation
- the doses should be available in different sizes, such that they can be easily selected by a user and administered by a dry powder inhaler device.
- the active substance in dry powder form suitable for inhalation needs to be finely divided so that the majority by mass of particles in the powder is between 1 and 5 ⁇ m in aerodynamic diameter (AD). Powder particles larger than 5 ⁇ m tend not to deposit in the lung, when inhaled, but to stick in the mouth and upper airways where they are medicinally wasted and may even cause adverse side effects.
- AD aerodynamic diameter
- WO 03/66470 A1 GB 02 385 020 A, and WO 03/15857 A1 an inhaler using compartments to hold the pharmaceutical formulation is described.
- the compartments have a first and a second face that will be sealed with a foil.
- a separate part inside each compartment is designed to rupture the foil before inhalation and the documents discuss weakening special sections in the foil to make the opening easier and more reliable.
- a dosage unit for dry powder medicaments is described.
- the dosage unit is possible to incorporate into a dry powder inhaler such as the one described in WO 02/00279, the dosage unit having a slidable chamber in a sleeve and an openable closure member possible to fit into the dry powder inhaler device.
- the dosage unit is described to have a cover of substantially the same diameter as the sleeve or being of a frangible material. A separate part inside the device will then push the cover open or rupture the frangible material.
- U.S. 2002/0033176 A1 a dry powder medicament inhalator is described, which is possible to load with a medicament cartridge.
- the inhalator uses an inhalation activated flow-diverting means for triggering the delivery of the medicament using a lancet to penetrate the medicament cartridge.
- Metered dose inhalers of prior art often leave the powder dose exposed to the surrounding atmosphere for a long time. This depends on the inhaler design and the design of the dose container. Barrier properties of the container embodiments are not discussed, leaving the question unanswered of how adequate protection is secured of the fine particle dose of the enclosed medicament during transportation, storing and in-use.
- opening of a container for a metered dose to make the dose accessible for inhalation inside a DPI is accomplished in many different ways. If dose capsules are used then e.g. the capsule is split in two and the content poured out in an intermediate area in the DPI from where the powder is later aerosolized. Another common method is to punch one or more holes in the capsule, blow air into the capsule and optionally vibrate the capsule such that the powder in the dose can be aerosolized and sucked out of the capsule. In the case of a blister container, the cover foil can be peeled off such that the dose is made available directly from the open blister or else poured out in an intermediate area for inhalation.
- a prior art container or capsule is thus opened in a first step and aerosolizing is begun in a second step.
- the time between step 1 and step 2 is different from one DPI to the next, depending on the deployed technical solution, but in many cases the period is not defined and can be anything up to minutes and hours depending on the actions of the user. This is not acceptable from a medical point of view if the dosage can be detrimentally affected by being exposed to the environment inside or outside of the DPI.
- edges of the broken container material will bend inwards towards the dose and the edges may then disturb the flow of air into the container, such that some parts of the dose are not properly aerosolized and de-aggregated.
- a certain suction power when applied to a suitably designed dry powder inhaler device (DPI), a certain suction power must first be applied to a mouthpiece of the DPI, before e.g. a valve opens to let air into the appropriate air channel in the DPI and further into a suction nozzle connected to the mouthpiece. This ensures that a fairly high air speed begins to build up around the inlet aperture of the suction nozzle.
- a seal opening operation is released simultaneously with opening of the air valve, but there is an interval before the opener contacts and penetrates the seal at one end of the container. In a relative motion, opener vs. container, the seal is gradually slit open and simultaneously folded away.
- the suction nozzle follows the opener in its track, but before the suction nozzle reaches the nearest dose particles inside the container, the air speed into the inlet aperture of the suction nozzle has already accelerated to a high speed, sufficient to de-aggregate the powder aggregates that are accessed a moment later. Following the opener closely in its track the powder in the dose is gradually aerosolized and de-aggregated at the same time. Keeping the distance constant between the inlet aperture of the suction nozzle and the dose bed, i.e.
- the container bottom ensures that the shearing power of the air stream going into the nozzle is evenly distributed and therefore used to its full potential in aerosolizing and de-aggregating all of the powder in the dose, regardless of where the powder is located on the dose bed of the container, presuming that the dose is in the area covered by the nozzle motion. Retention is minimized.
- the time period between exposing the dose to the atmosphere and delivering the dose to the airways of a user is clearly extremely short, normally only fractions of a second, ensuring that the dose is as unaffected as possible by the surrounding atmosphere, when inhaled.
- the folded edges of the cut seal may be folded back in the original position by the DPI, which closes, at least partially, the container so that any powder retained in the container does not fall out into the mechanisms of the DPI or into an air channel, where the powder may affect the operation of the DPI or present a risk to the user.
- any one, two or more parts may move so as to accomplish the intended function.
- the dose can move, or both the nozzle and dose can move towards one another.
- the dose can be moved towards the opener and suction nozzle, or the opener/nozzle and dose can move towards one another.
- the present invention thus discloses a manually operated dry powder inhaler device (DPI) that relies partially or totally on power provided by a user for delivering dry powder medication doses.
- the device is capable of delivering an enclosed dose directly from a medicament container, inserted into the DPI. Dose delivery can be manually activated by a user of the inhaler device.
- a method is also disclosed for delivering a dry powder medicament dose directly from a sealed dose container to a user of a DPI. A seal sealing the dose container is optionally opened concurrently with a release of the dose and aerosolization of the powder into the inhalation airstream.
- An objective of the present invention is that the dose container, when made available in a DPI, is not opened until a user starts to inhale through the DPI, thereby exerting a suction power exceeding a set minimum pressure before the dose container is opened.
- a sealing foil is opened in a relative motion of an opener vis-à-vis the container, where the speed of motion is controlled by the user.
- Another objective of the present invention is that the speed of the air stream into the DPI resulting from the inhalation is built up to exceed a set, minimum speed before the air stream is directed to the powder in the dose.
- a sealing foil being opened is folded away from the dose, whereby a suction nozzle gets free access to all of the powder in the dose during the inhalation.
- a dry powder inhaler device which is adapted to receiving a dose container with an enclosed metered dose.
- the container is opened by an opener when at least a minimum suction has been applied to the device and the powder in the enclosed dose of the container is sucked up by a suction nozzle when a minimum speed of the air flow into the nozzle has been exceeded.
- FIG. 1 illustrates a side view of an embodiment of the invention
- FIG. 2 illustrates a top view of an embodiment of the invention.
- the present invention discloses a novel type of manually operated, dry powder inhaler device (DPI) adapted for accepting a dose container enclosing a metered dry powder dose.
- the disclosed inhaler device is preferably a single dose inhaler relying on the power of a user for delivering dry powder doses of medicaments.
- the inhaler device can have a movable slide, which is intended to be loaded with a replaceable dose container by a user. The user inserts the dose container into the inhaler body, for example by pushing the slide into the body by hand force. When the dose in the dose container has been delivered by the DPI, the slide is brought out of the inhaler body, at any convenient point in time.
- a new container with a new dose may be administered by the user of the DPI on an as-needed basis.
- An alternative is a sealed dose container with multiple sealed doses.
- the dose to be delivered after the first dose can move into position with the action of the user in administering the preceding dose, and/or can be moved by an external force such as, for example, through the actuation of a mechanical mechanism or by physical manipulation.
- the multiple doses can be arranged in any spatial manner, and in one embodiment can be compared to a ribbon of ammunition being fed into a machine gun.
- each dose is kept intact by a high barrier seal, which effectively seals the container from ingress of foreign matter, especially moisture, until the container is opened in direct connection with inhalation of the enclosed dose.
- the user pushes the slide into the inhaler body with a generally constant speed using a relatively light force at the same time as he or she inhales through a mouthpiece of the inhaler.
- the container seal is thereby brought into contact with an opener that slits the foil and folds it away from the enclosed dose.
- This action makes the dose available to a suction nozzle, such that the stream of air entering the inhaler flows into the inlet aperture of the suction nozzle at high speed.
- the dose is thereby released, aerosolized and de-aggregated gradually while the container is being carried past the container opener and the suction nozzle by the user operated slide.
- the speed of the slide motion while pushed by the user is prevented from becoming too high by a damping mechanism, such that an increase in user driving force is met with an increased opposing force.
- the slide is locked by a catch in its first, loading position so that it cannot move when the user exerts a low to moderate force on the slide, i.e. not until the user also applies a certain minimum suction effort to the mouthpiece of the inhaler.
- a flap or similar arrangement opens for air to be sucked in and at the same time releases the catch holding the slide so that the user can begin to push the slide and dose container into the inhaler body, whereby the dose gets delivered gradually.
- a preferred embodiment of the present invention comprises an overriding rescue mechanism, which is activated when the user exerts a high force on the slide, i.e. a force considerably higher than the normal low to moderate force, whereby the catch releases the slide and the flap opens even if no or too low suction is present at the mouthpiece. In a panic situation, therefore, the user can still get a reasonable dosage even if he or she cannot synchronize the pushing and the suction perfectly.
- FIGS. 1 and 2 reference numbers 10 - 14 of the drawings, like numbers indicate like elements throughout the several views of the embodiment of an inhaler device as illustrated, presented here as a non-limiting example.
- FIG. 1 illustrates a side view of an embodiment of the invention, where 10 designates the inhaler body, 11 designates the mouthpiece, 12 designates the slide and 13 designates the end of the slide, where the user exerts a force by the hand to push the slide into the inhaler body.
- FIG. 2 illustrates a top view of the embodiment, also indicating the position 14 for a loaded dose container.
- a container and an enclosed dose or doses are loaded into a DPI for a later user initiated dose delivery concurrent with a simultaneous opening of the container.
- Another particular embodiment of the present invention comprises a slitting element, an opener, which slits the seal from a point of penetration at a first end of the dose container to a point of exit at a second end of the dose container.
- the point of penetration of the seal is not necessarily the same as the point of exit.
- a selected, sealed dose container inserted in a DPI is opened and the enclosed, metered dose is sucked up by a suction nozzle during a single inhalation, whereby the delivered fine particle dose by weight amounts to at least 30%, preferably at least 50% and most preferably at least 70% or more of the active pharmaceutical ingredient(s) of the metered dose.
- Another preferred embodiment of the present invention is a sealed dose container and inhaler, which, when the dose container is being opened and powder is being sucked up by a nozzle, present consistent airflow conditions and equal dose accessibility for the airflow into the suction nozzle during a dose delivery sequence.
- Another particular embodiment of the present invention is a sealed container and inhaler arrangement, where the seal is slit open and folded away from the dose, such that the dose is efficiently aerosolized into a suction nozzle, provided at least a minimum of suction power is applied to the nozzle, whereby retention of powder in the container is minimized and not exceeding 20%, preferably not exceeding 10% and most preferably not exceeding 5% of the active pharmaceutical ingredient(s) of the metered dose by weight.
- a dry powder inhaler device which arranges dose containers, if more than one, for a user initiated administration and delivery of one or more metered dose per inhalation.
- one dose container at a time is arranged by the inhaler for delivery of the enclosed, metered dose in a single inhalation by a user.
- the design of the inhaler controls how dose containers are to be inserted into the inhaler and the number of dose containers, which may be inserted and used before it becomes necessary to provide a new set of dose containers.
- Another embodiment requires that at least one dose container is first mounted onto a container carrier, which is then loaded into the inhaler.
- Areas of therapy where the present invention is advantageously applied include asthma, COPD and pain, but other examples of therapy areas, not limiting the scope of the invention, are non-exclusively:
- the present invention may be used for delivering single medicaments or combinations of medicaments in combined doses in a single delivery by an inhalation route.
- the invention improves the quality of treatment, lowers the cost, and improves quality of life for users.
- Non-limiting examples of suitable medicaments in dry powder form which are suitable for delivery of dosages by the present invention—whether in pure or diluted formulations, in single preparations or in combination with other active and/or inactive substances—include insulin, sumatriptan, fluticasone, formoterol and tiotropium to name but a few.
- “Dry” as used herein means that the, e.g., walls of the container are constructed from selected materials and/or materials treated such that the walls, especially the inside wall surface of the container, cannot release water that may affect the medication powder in the dose such that the fine particle dose (FPD) is reduced.
- container construction and materials should not be in need of processes suggested in the German publication DE 101 26 924 A 1 (US2003070679).
- gelatin is not a dry material and even after a special drying process gelatin still contains water.
- “dry” means the medicament FPD is not affected by the concerned material.
- High barrier seal means a dry packaging construction or material or combinations of materials.
- a high barrier seal represents a high barrier against moisture and other foreign matter, and the seal itself is ‘dry’, i.e. it cannot give off measurable amounts of water to the load of powder.
- a high barrier seal may for instance be made up of one or more layers of materials, i.e. technical polymers, aluminum or other metals, glass, silicon oxides etc that together constitute the high barrier seal. If the high barrier seal is a foil a 50 ⁇ m PCTFE/PVC pharmaceutical foil is a particularly useful high barrier foil. For longer in-use stability, metal foils like aluminum foils from Alcan Packaging Lawson Mardon Singen GmbH is a preferred choice.
- a “high barrier container” is a mechanical construction made to harbor and enclose a dose of e.g. tiotropium.
- the high barrier container is built using high barrier seals constituting the walls of the container.
- the term “container” is used in this document to describe a high barrier container, characterized by having a bottom suitable for receiving a metered dose of a dry powder, either by volumetric or electrodynamic filling methods, and further characterized in being sealed by a foil, which may be slit open by a opener such that the enclosed dose may be accessed by a suction nozzle.
- Directly loaded means that the metered dose is loaded directly into the high barrier container, i.e. without first filling the dose into e.g. a gelatin capsule, and then enclosing one or more of the primary containers (capsules) in a secondary package made of a high barrier seal material.
- the high barrier containers to be loaded with medicament doses are preferably made out of aluminum foils approved to be in direct contact with pharmaceutical products.
- Aluminum foils that work properly in these aspects generally are composed of technical polymers laminated with aluminum foil to give the foil the correct mechanical properties to avoid cracking of the aluminum during forming. Sealing of the formed containers is normally done by using a thinner cover foil of pure aluminum or laminated aluminum and polymer. The container and cover foils are then sealed together using at least one of several possible methods, for instance:
- the sealed container of the invention that is directly loaded with a formulation of a medicament preferably comprises a flat or curved dose bed, e.g. a formed cavity in aluminum foil or a molded cavity in a polymer material, using a high barrier seal foil against ingress of moisture and other foreign matter, e.g. of aluminum or a combination of aluminum and polymer materials.
- the sealed, dry, high barrier container may form a part of an inhaler device or it may form a part of a separate item intended for insertion into an inhaler device for administration of dose(s).
- the sealed container may e.g. have the following data, as a non-limiting example:
- a high barrier container may be made quite small and may contain from micrograms to many milligrams of dose, depending on the active substance and its potency.
- the inhaler device according to the present invention may also be made very small, for example not larger than a credit card except for the thickness, making it possible for a user to carry the inhaler almost anywhere.
- Some prior art inhaler devices make it necessary to open the container and empty the dose into an aerosolizing chamber before the user can begin an inhalation cycle.
- the dose may get exposed to a voluntary or involuntary exhalation from the user before a proper inhalation cycle begins.
- the container is opened by a first action by the user but the act of inhaling from the opened container is delayed uncontrollably, because the user is somehow distracted. Exposing the powder dose to the atmosphere for any reason, including technical shortcomings of the container-inhaler combination, must be kept as short as possible so that the quality of the dose cannot deteriorate before it is inhaled. Also, preferably there should be no room for behavioral errors on behalf of the user.
- a device which closes a DPI, should the user exhale, so that exhalation air does not reach the dose container and the selected dose in the DPI.
- the device also controls the release of an opener and a suction nozzle such that the opener cannot open the container and inspiration air cannot begin to aerosolize the dose until a certain selected pressure drop is first present due to a suction effort by the user.
- An inhaler providing a prolonged delivery of a dose during the course of a single inhalation from a high barrier seal container produced from aluminium foils constitutes a preferred embodiment of an inhaler for the delivery of a dry powder medicament formulation.
- An Air-razor method as described in U.S. Pat. No. 6,840,239 and an Air-razor device as described in U.S. Pat. No. 6,892,727, which are incorporated herein by reference, are preferably applied in the inhaler to efficiently and gradually aerosolize the dose when delivered to the user.
- a single dose inhaler device should preferably be provided such that
- the phrases “selected from the group consisting of,” “chosen from,” and the like include mixtures of the specified materials.
- a medicament container enclosing a dry powder medicament dose for use in a dry powder inhaler, characterized in that a first component of the dry powder medicament consists of a fine particle dose of at least one pharmacologically active ingredient; the container constitutes a dry, high barrier seal, whereby the high barrier seal of the container prevents ingress of foreign matter, especially moisture, thereby preserving the original fine particle fraction of the dry powder dose; and the dry powder medicament dose in the container is adapted for either volumetric or electric field dose forming methods.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Anesthesiology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
Abstract
A dry powder inhaler device (DPI) is disclosed. When a user activates the inhaler, the DPI is capable of delivering a dry powder dose directly from a medicament container, loaded into the DPI. A method is also disclosed for delivering a dry powder medicament dose directly from a container to a user of a DPI, whereby a sealing foil of the container is being slit open concurrently with aerosolizing and entraining of the powder in the dose into the inhaled air.
Description
- This application claims priority to Swedish patent application SE0401453-6 filed Jun. 7, 2004, incorporated herein by reference.
- The present invention relates to a dry powder inhaler device for metered dry powder medicament doses, and particularly to a single dose inhaler. In a preferred embodiment the inhaler is one relying on a user providing a necessary action/force in order to deliver a selected dose made available in the inhaler.
- Additional advantages and other features of the present invention will be set forth in part in the description that follows and in part will become apparent to those having ordinary skill in the art upon examination of the following or may be learned from the practice of the present invention. The advantages of the present invention may be realized and obtained as particularly pointed out in the appended claims. As will be realized, the present invention is capable of other and different embodiments, and its several details are capable of modifications in various obvious respects, all without departing from the present invention. The description is to be regarded as illustrative in nature, and not as restrictive.
- The dosing of drugs is carried out in a number of different ways in the medical service today. Within health care there is a rapidly growing interest in the possibility of administering medication drugs as a powder directly to the airways and lungs of a patient by means of an inhaler in order to obtain an effective, quick and user-friendly delivery of such substances. Because the efficacy of inhaled doses often are much higher than e.g. orally administered capsules, the inhalation doses need only be a fraction of the medicament powder mass in an oral capsule. Thus, there is an increasing demand for medicament compositions and small and exact inhalation doses of dry powder with low relative standard deviation (RSD). The doses should be available in different sizes, such that they can be easily selected by a user and administered by a dry powder inhaler device.
- The active substance in dry powder form, suitable for inhalation needs to be finely divided so that the majority by mass of particles in the powder is between 1 and 5 μm in aerodynamic diameter (AD). Powder particles larger than 5 μm tend not to deposit in the lung, when inhaled, but to stick in the mouth and upper airways where they are medicinally wasted and may even cause adverse side effects.
- In WO 02/00280 A2 and U.S. Pat. No. 6,655,381 B2, an inhaler comprising a magazine holding a rigid unitary magazine including a plurality of integral reservoirs is described. Each reservoir will hold a pre-metered dose of dry powder sealed with a foil.
- In WO 03/66470 A1, GB 02 385 020 A, and WO 03/15857 A1 an inhaler using compartments to hold the pharmaceutical formulation is described. The compartments have a first and a second face that will be sealed with a foil. A separate part inside each compartment is designed to rupture the foil before inhalation and the documents discuss weakening special sections in the foil to make the opening easier and more reliable.
- In WO 01/30430 A1 a dosage unit for dry powder medicaments is described. The dosage unit is possible to incorporate into a dry powder inhaler such as the one described in WO 02/00279, the dosage unit having a slidable chamber in a sleeve and an openable closure member possible to fit into the dry powder inhaler device. The dosage unit is described to have a cover of substantially the same diameter as the sleeve or being of a frangible material. A separate part inside the device will then push the cover open or rupture the frangible material.
- In U.S. 2002/0033176 A1 a dry powder medicament inhalator is described, which is possible to load with a medicament cartridge. The inhalator uses an inhalation activated flow-diverting means for triggering the delivery of the medicament using a lancet to penetrate the medicament cartridge.
- Metered dose inhalers of prior art, as in the above examples, often leave the powder dose exposed to the surrounding atmosphere for a long time. This depends on the inhaler design and the design of the dose container. Barrier properties of the container embodiments are not discussed, leaving the question unanswered of how adequate protection is secured of the fine particle dose of the enclosed medicament during transportation, storing and in-use.
- Thus, there is a need for improved dry powder medicament doses loaded in high integrity dose containers adapted for insertion into dry powder inhalers guaranteeing consistent high quality administration of such doses.
- In prior art, opening of a container for a metered dose to make the dose accessible for inhalation inside a DPI is accomplished in many different ways. If dose capsules are used then e.g. the capsule is split in two and the content poured out in an intermediate area in the DPI from where the powder is later aerosolized. Another common method is to punch one or more holes in the capsule, blow air into the capsule and optionally vibrate the capsule such that the powder in the dose can be aerosolized and sucked out of the capsule. In the case of a blister container, the cover foil can be peeled off such that the dose is made available directly from the open blister or else poured out in an intermediate area for inhalation.
- A prior art container or capsule is thus opened in a first step and aerosolizing is begun in a second step. The time between step 1 and step 2 is different from one DPI to the next, depending on the deployed technical solution, but in many cases the period is not defined and can be anything up to minutes and hours depending on the actions of the user. This is not acceptable from a medical point of view if the dosage can be detrimentally affected by being exposed to the environment inside or outside of the DPI.
- Yet another drawback of prior art containers is that the stream of air sucked in to aerosolize the dose attacks all of the powder in the dose at the same time, so that the shearing power of the air stream is distributed over a large area where the dose is stored and the aggregates and particles in the dose are arbitrarily subjected to very different, uncontrolled shearing forces depending on how the powder and particle clusters in the dose are distributed relative the air stream. Most of the powder in the dose is delivered instantaneously with no control of the timing. Where holes are made in the container, e.g. a capsule or a blister, by a sharp, pointed tool or needle, edges of the broken container material will bend inwards towards the dose and the edges may then disturb the flow of air into the container, such that some parts of the dose are not properly aerosolized and de-aggregated.
- In some cases all of the powder in the dose is not subjected to the same power of shearing stress because the airflow is unevenly distributed across or through the dose. This tends to further hamper the delivered fine particle dose and raise the proportion of retained powder in the container.
- Another problem is incident to aerosolizing a dose in a prior art container and that is that the speed of the aerosolizing air stream starts at zero when the aerosolization process begins. The consequence is that most of the dose is quickly sucked up in aggregated form and the aggregates cannot then be completely de-aggregated during the transport through the air channel of the DPI before entering the airways of the user.
- Because of these drawbacks a high degree of de-aggregation is difficult to achieve consistently, and the delivered fine particle dose is relatively small as a percentage of the metered dose.
- The present invention, on the other hand, solves these problems. In a preferred embodiment of the present invention, when applied to a suitably designed dry powder inhaler device (DPI), a certain suction power must first be applied to a mouthpiece of the DPI, before e.g. a valve opens to let air into the appropriate air channel in the DPI and further into a suction nozzle connected to the mouthpiece. This ensures that a fairly high air speed begins to build up around the inlet aperture of the suction nozzle. A seal opening operation is released simultaneously with opening of the air valve, but there is an interval before the opener contacts and penetrates the seal at one end of the container. In a relative motion, opener vs. container, the seal is gradually slit open and simultaneously folded away. The suction nozzle follows the opener in its track, but before the suction nozzle reaches the nearest dose particles inside the container, the air speed into the inlet aperture of the suction nozzle has already accelerated to a high speed, sufficient to de-aggregate the powder aggregates that are accessed a moment later. Following the opener closely in its track the powder in the dose is gradually aerosolized and de-aggregated at the same time. Keeping the distance constant between the inlet aperture of the suction nozzle and the dose bed, i.e. the container bottom, ensures that the shearing power of the air stream going into the nozzle is evenly distributed and therefore used to its full potential in aerosolizing and de-aggregating all of the powder in the dose, regardless of where the powder is located on the dose bed of the container, presuming that the dose is in the area covered by the nozzle motion. Retention is minimized. The time period between exposing the dose to the atmosphere and delivering the dose to the airways of a user is clearly extremely short, normally only fractions of a second, ensuring that the dose is as unaffected as possible by the surrounding atmosphere, when inhaled.
- The folded edges of the cut seal may be folded back in the original position by the DPI, which closes, at least partially, the container so that any powder retained in the container does not fall out into the mechanisms of the DPI or into an air channel, where the powder may affect the operation of the DPI or present a risk to the user.
- In all instances where movement occurs herein between parts in the practice of the invention, any one, two or more parts may move so as to accomplish the intended function. For example, rather than the nozzle moving, as noted above, the dose can move, or both the nozzle and dose can move towards one another. For example, the dose can be moved towards the opener and suction nozzle, or the opener/nozzle and dose can move towards one another.
- The present invention thus discloses a manually operated dry powder inhaler device (DPI) that relies partially or totally on power provided by a user for delivering dry powder medication doses. The device is capable of delivering an enclosed dose directly from a medicament container, inserted into the DPI. Dose delivery can be manually activated by a user of the inhaler device. A method is also disclosed for delivering a dry powder medicament dose directly from a sealed dose container to a user of a DPI. A seal sealing the dose container is optionally opened concurrently with a release of the dose and aerosolization of the powder into the inhalation airstream.
- An objective of the present invention is that the dose container, when made available in a DPI, is not opened until a user starts to inhale through the DPI, thereby exerting a suction power exceeding a set minimum pressure before the dose container is opened. In a particular embodiment a sealing foil is opened in a relative motion of an opener vis-à-vis the container, where the speed of motion is controlled by the user.
- Another objective of the present invention is that the speed of the air stream into the DPI resulting from the inhalation is built up to exceed a set, minimum speed before the air stream is directed to the powder in the dose.
- In a particular aspect of the invention a sealing foil being opened is folded away from the dose, whereby a suction nozzle gets free access to all of the powder in the dose during the inhalation.
- In still another aspect of the present invention a dry powder inhaler device is disclosed, which is adapted to receiving a dose container with an enclosed metered dose. The container is opened by an opener when at least a minimum suction has been applied to the device and the powder in the enclosed dose of the container is sucked up by a suction nozzle when a minimum speed of the air flow into the nozzle has been exceeded.
- The invention, together with further objects and advantages thereof, may best be understood by referring to the following detailed description taken together with the accompanying drawings, in which:
-
FIG. 1 illustrates a side view of an embodiment of the invention, and -
FIG. 2 illustrates a top view of an embodiment of the invention. - The present invention discloses a novel type of manually operated, dry powder inhaler device (DPI) adapted for accepting a dose container enclosing a metered dry powder dose. The disclosed inhaler device is preferably a single dose inhaler relying on the power of a user for delivering dry powder doses of medicaments. The inhaler device can have a movable slide, which is intended to be loaded with a replaceable dose container by a user. The user inserts the dose container into the inhaler body, for example by pushing the slide into the body by hand force. When the dose in the dose container has been delivered by the DPI, the slide is brought out of the inhaler body, at any convenient point in time. The user then can remove the spent container and can, if desired, push the now empty slide again into the inhaler body or, for example, load a new dose container into the slide in preparation of a new dose delivery. In this manner a new container with a new dose may be administered by the user of the DPI on an as-needed basis. An alternative is a sealed dose container with multiple sealed doses. The dose to be delivered after the first dose can move into position with the action of the user in administering the preceding dose, and/or can be moved by an external force such as, for example, through the actuation of a mechanical mechanism or by physical manipulation. The multiple doses can be arranged in any spatial manner, and in one embodiment can be compared to a ribbon of ammunition being fed into a machine gun. Preferably, each dose is kept intact by a high barrier seal, which effectively seals the container from ingress of foreign matter, especially moisture, until the container is opened in direct connection with inhalation of the enclosed dose.
- In a preferred embodiment of the present invention the user pushes the slide into the inhaler body with a generally constant speed using a relatively light force at the same time as he or she inhales through a mouthpiece of the inhaler. The container seal is thereby brought into contact with an opener that slits the foil and folds it away from the enclosed dose. This action makes the dose available to a suction nozzle, such that the stream of air entering the inhaler flows into the inlet aperture of the suction nozzle at high speed. The dose is thereby released, aerosolized and de-aggregated gradually while the container is being carried past the container opener and the suction nozzle by the user operated slide.
- In a particular embodiment of the present invention the speed of the slide motion while pushed by the user is prevented from becoming too high by a damping mechanism, such that an increase in user driving force is met with an increased opposing force.
- Preferably, the slide is locked by a catch in its first, loading position so that it cannot move when the user exerts a low to moderate force on the slide, i.e. not until the user also applies a certain minimum suction effort to the mouthpiece of the inhaler. Then, a flap or similar arrangement opens for air to be sucked in and at the same time releases the catch holding the slide so that the user can begin to push the slide and dose container into the inhaler body, whereby the dose gets delivered gradually.
- A preferred embodiment of the present invention comprises an overriding rescue mechanism, which is activated when the user exerts a high force on the slide, i.e. a force considerably higher than the normal low to moderate force, whereby the catch releases the slide and the flap opens even if no or too low suction is present at the mouthpiece. In a panic situation, therefore, the user can still get a reasonable dosage even if he or she cannot synchronize the pushing and the suction perfectly.
- In
FIGS. 1 and 2 reference numbers 10-14 of the drawings, like numbers indicate like elements throughout the several views of the embodiment of an inhaler device as illustrated, presented here as a non-limiting example. -
FIG. 1 illustrates a side view of an embodiment of the invention, where 10 designates the inhaler body, 11 designates the mouthpiece, 12 designates the slide and 13 designates the end of the slide, where the user exerts a force by the hand to push the slide into the inhaler body. -
FIG. 2 illustrates a top view of the embodiment, also indicating theposition 14 for a loaded dose container. - In a particular embodiment of the present invention a container and an enclosed dose or doses are loaded into a DPI for a later user initiated dose delivery concurrent with a simultaneous opening of the container.
- Another particular embodiment of the present invention comprises a slitting element, an opener, which slits the seal from a point of penetration at a first end of the dose container to a point of exit at a second end of the dose container. Thus, the point of penetration of the seal is not necessarily the same as the point of exit.
- In a further preferred embodiment of the present invention, a selected, sealed dose container inserted in a DPI is opened and the enclosed, metered dose is sucked up by a suction nozzle during a single inhalation, whereby the delivered fine particle dose by weight amounts to at least 30%, preferably at least 50% and most preferably at least 70% or more of the active pharmaceutical ingredient(s) of the metered dose.
- Another preferred embodiment of the present invention is a sealed dose container and inhaler, which, when the dose container is being opened and powder is being sucked up by a nozzle, present consistent airflow conditions and equal dose accessibility for the airflow into the suction nozzle during a dose delivery sequence.
- Another particular embodiment of the present invention is a sealed container and inhaler arrangement, where the seal is slit open and folded away from the dose, such that the dose is efficiently aerosolized into a suction nozzle, provided at least a minimum of suction power is applied to the nozzle, whereby retention of powder in the container is minimized and not exceeding 20%, preferably not exceeding 10% and most preferably not exceeding 5% of the active pharmaceutical ingredient(s) of the metered dose by weight.
- According to the present invention a dry powder inhaler device is disclosed, which arranges dose containers, if more than one, for a user initiated administration and delivery of one or more metered dose per inhalation. In one embodiment of the invention one dose container at a time is arranged by the inhaler for delivery of the enclosed, metered dose in a single inhalation by a user. The design of the inhaler controls how dose containers are to be inserted into the inhaler and the number of dose containers, which may be inserted and used before it becomes necessary to provide a new set of dose containers. Another embodiment requires that at least one dose container is first mounted onto a container carrier, which is then loaded into the inhaler.
- Areas of therapy where the present invention is advantageously applied include asthma, COPD and pain, but other examples of therapy areas, not limiting the scope of the invention, are non-exclusively:
- Disorders of the alimentary tract or the digestive system
- Disorders of the cardiovascular system
- Disorders of the endocrine system
- Disorders of the respiratory system
- Genital or sexual disorders
- Disorders of the muscular or neuromuscular system
- Disorders of the nervous system
- Psychosomatic disorders
- Anti-infectives
- Allergic disorders
- Protective or antinoxious agents
- The present invention may be used for delivering single medicaments or combinations of medicaments in combined doses in a single delivery by an inhalation route. The invention improves the quality of treatment, lowers the cost, and improves quality of life for users.
- Non-limiting examples of suitable medicaments in dry powder form, which are suitable for delivery of dosages by the present invention—whether in pure or diluted formulations, in single preparations or in combination with other active and/or inactive substances—include insulin, sumatriptan, fluticasone, formoterol and tiotropium to name but a few.
- “Dry” as used herein means that the, e.g., walls of the container are constructed from selected materials and/or materials treated such that the walls, especially the inside wall surface of the container, cannot release water that may affect the medication powder in the dose such that the fine particle dose (FPD) is reduced. As a logical consequence, container construction and materials should not be in need of processes suggested in the German publication DE 101 26 924 A 1 (US2003070679). As an example, gelatin is not a dry material and even after a special drying process gelatin still contains water. Generally, “dry” means the medicament FPD is not affected by the concerned material.
- “High barrier seal” means a dry packaging construction or material or combinations of materials. A high barrier seal represents a high barrier against moisture and other foreign matter, and the seal itself is ‘dry’, i.e. it cannot give off measurable amounts of water to the load of powder. A high barrier seal may for instance be made up of one or more layers of materials, i.e. technical polymers, aluminum or other metals, glass, silicon oxides etc that together constitute the high barrier seal. If the high barrier seal is a foil a 50 μm PCTFE/PVC pharmaceutical foil is a particularly useful high barrier foil. For longer in-use stability, metal foils like aluminum foils from Alcan Packaging Lawson Mardon Singen GmbH is a preferred choice.
- A “high barrier container” is a mechanical construction made to harbor and enclose a dose of e.g. tiotropium. The high barrier container is built using high barrier seals constituting the walls of the container. The term “container” is used in this document to describe a high barrier container, characterized by having a bottom suitable for receiving a metered dose of a dry powder, either by volumetric or electrodynamic filling methods, and further characterized in being sealed by a foil, which may be slit open by a opener such that the enclosed dose may be accessed by a suction nozzle.
- “Directly loaded” means that the metered dose is loaded directly into the high barrier container, i.e. without first filling the dose into e.g. a gelatin capsule, and then enclosing one or more of the primary containers (capsules) in a secondary package made of a high barrier seal material.
- The high barrier containers to be loaded with medicament doses are preferably made out of aluminum foils approved to be in direct contact with pharmaceutical products. Aluminum foils that work properly in these aspects generally are composed of technical polymers laminated with aluminum foil to give the foil the correct mechanical properties to avoid cracking of the aluminum during forming. Sealing of the formed containers is normally done by using a thinner cover foil of pure aluminum or laminated aluminum and polymer. The container and cover foils are then sealed together using at least one of several possible methods, for instance:
-
- using a heat sealing lacquer, through pressure and heat;
- using heat and pressure to fuse the materials together;
- ultrasonic welding of the materials in contact.
- The sealed container of the invention that is directly loaded with a formulation of a medicament preferably comprises a flat or curved dose bed, e.g. a formed cavity in aluminum foil or a molded cavity in a polymer material, using a high barrier seal foil against ingress of moisture and other foreign matter, e.g. of aluminum or a combination of aluminum and polymer materials. The sealed, dry, high barrier container may form a part of an inhaler device or it may form a part of a separate item intended for insertion into an inhaler device for administration of dose(s). The sealed container may e.g. have the following data, as a non-limiting example:
-
- Container internal volume: 100 mm3
- Effective diffusion area: 46 mm2
- Diffusion constant: 0.044 g/m2 for 24 hours at 23° C. and differential Rh=50%
- A high barrier container may be made quite small and may contain from micrograms to many milligrams of dose, depending on the active substance and its potency. The inhaler device according to the present invention may also be made very small, for example not larger than a credit card except for the thickness, making it possible for a user to carry the inhaler almost anywhere.
- Some prior art inhaler devices make it necessary to open the container and empty the dose into an aerosolizing chamber before the user can begin an inhalation cycle. In some cases the dose may get exposed to a voluntary or involuntary exhalation from the user before a proper inhalation cycle begins. In some inhalers the container is opened by a first action by the user but the act of inhaling from the opened container is delayed uncontrollably, because the user is somehow distracted. Exposing the powder dose to the atmosphere for any reason, including technical shortcomings of the container-inhaler combination, must be kept as short as possible so that the quality of the dose cannot deteriorate before it is inhaled. Also, preferably there should be no room for behavioral errors on behalf of the user.
- To protect the FPD up to the very point of aerosolizing of the dose a method of opening the dose container a fraction of a second before the dose starts to be aerosolized is described in WO 02/24266 A1 (U.S. Pat. No. 6,651,341), which is incorporated herein by reference. In this context it is also important to prevent a voluntary or involuntary exhalation from a user of a DPI, who is about to inhale a dose, from reaching the selected dose, because of the high moisture content in the exhalation air. In U.S. Pat. No. 6,439,227 B1, which is incorporated herein by reference, a device is disclosed, which closes a DPI, should the user exhale, so that exhalation air does not reach the dose container and the selected dose in the DPI. The device also controls the release of an opener and a suction nozzle such that the opener cannot open the container and inspiration air cannot begin to aerosolize the dose until a certain selected pressure drop is first present due to a suction effort by the user.
- An inhaler providing a prolonged delivery of a dose during the course of a single inhalation from a high barrier seal container produced from aluminium foils constitutes a preferred embodiment of an inhaler for the delivery of a dry powder medicament formulation. An Air-razor method as described in U.S. Pat. No. 6,840,239 and an Air-razor device as described in U.S. Pat. No. 6,892,727, which are incorporated herein by reference, are preferably applied in the inhaler to efficiently and gradually aerosolize the dose when delivered to the user.
- Summarizing certain important aspects of a preferable embodiment of the present invention, a single dose inhaler device should preferably be provided such that
-
- the operation of the inhaler is powered and controlled by the user, who provides hand force to push a dose container into the inhaler and open the container to make the dose accessible for a concurrent suction effort by the user, which releases and aerosolizes the enclosed dose into an inhalation airstream;
- a seal of the container is arranged such that an opener, when in motion relative the container, penetrates the seal at one or more points of the container. The opener slits the seal open and exits the seal preferably at different point(s) of the container, such that the point(s) of penetration is(are) preferably different from the point(s) of exit of the foil;
- the opener folds the slitted seal away from the powder dose, such that a suction nozzle following the opener in its track can access the powder dose;
- the slitted, folded seal can be folded back into approximately the original, closed position by a suitable arrangement in the inhaler device, whereby retained powder cannot easily escape from the dose container;
- the bottom dose bed area of the container carrying the dose is arranged, such that the distance between the dose bed and the suction nozzle can be kept reasonably constant to ensure consistent airflow conditions during dose delivery.
- As used herein, the phrases “selected from the group consisting of,” “chosen from,” and the like include mixtures of the specified materials.
- All references, patents, applications, tests, standards, documents, publications, brochures, texts, articles, instructions, etc. mentioned herein are incorporated herein by reference. Where a numerical limit or range is stated, the endpoints are included. Also, all values and sub-ranges within a numerical limit or range are specifically included as if explicitly written out.
- The above written description of the invention provides a manner and process of making and using it such that any person skilled in this art is enabled to make and use the same, this enablement being provided in particular for the subject matter of the appended claims, which make up a part of the original description and including a medicament container enclosing a dry powder medicament dose for use in a dry powder inhaler, characterized in that a first component of the dry powder medicament consists of a fine particle dose of at least one pharmacologically active ingredient; the container constitutes a dry, high barrier seal, whereby the high barrier seal of the container prevents ingress of foreign matter, especially moisture, thereby preserving the original fine particle fraction of the dry powder dose; and the dry powder medicament dose in the container is adapted for either volumetric or electric field dose forming methods.
- What has been said in the foregoing is by example only and many variations to the disclosed 15 embodiments may be obvious to a person of ordinary skill in the art, without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (20)
1. A dry powder inhaler device comprising a moveable slide adapted to be loaded with a replaceable medicament container enclosing at least one metered, dry powder medication dose, a container opener and a suction nozzle in fluid connection with a mouthpiece,
wherein said device is arranged such that when a user moves the slide from a first position to a second position by applying force on the slide at the same time as carrying out an inhalation the container is opened by the opener and the enclosed medication dose is sucked up and delivered by the suction nozzle and mouthpiece to the inhaling user while the slide is being pushed from the first to the second position in the inhaler device.
2. The inhaler device according to claim 1 , further comprising a suction dependent catch release, and wherein the slide is locked in the first position until a suction dependent catch releases it.
3. The inhaler device according to claim 2 , wherein
the catch is released by a suction effort exceeding a selected value applied to the mouthpiece.
4. The inhaler device according to claim 2 , wherein
an initial, higher force applied to the slide releases the catch such that the container when loaded into said slide may be pushed from the first to the second position using lower force.
5. The inhaler device according to claim 2 , wherein
a damper exerts an opposing force to the force provided by the user on the slide, such that a speed of the slide when in motion is moderated.
6. The inhaler device according to claim 1 , wherein said device is arranged such that the medication dose is released gradually while the slide is being pushed from the first to the second position in the inhaler device.
7. The inhaler device according to claim 1 , wherein the container opener is arranged to slit a seal of said container and fold the seal away from a dose in the container such that the suction nozzle gets full access to the powder in the dose, while the slide is being pushed from the first to the second position in the inhaler device.
8. The inhaler device according to claim 7 , wherein
the slit seal is folded back into its original position in the container when the slide is moved from the second position into the first position.
9. The inhaler device according to claim 1 , loaded with said replaceable medicament container enclosing at least one metered, dry powder medication dose.
10. The inhaler device according to claim 2 , loaded with said replaceable medicament container enclosing at least one metered, dry powder medication dose.
11. The inhaler device according to claim 3 , loaded with said replaceable medicament container enclosing at least one metered, dry powder medication dose.
12. The inhaler device according to claim 4 , loaded with said replaceable medicament container enclosing at least one metered, dry powder medication dose.
13. The inhaler device according to claim 5 , loaded with said replaceable medicament container enclosing at least one metered, dry powder medication dose.
14. The inhaler device according to claim 6 , loaded with said replaceable medicament container enclosing at least one metered, dry powder medication dose.
15. The inhaler device according to claim 7 , loaded with said replaceable medicament container enclosing at least one metered, dry powder medication dose.
16. The inhaler device according to claim 8 , loaded with said replaceable medicament container enclosing at least one metered, dry powder medication dose.
17. A method, comprising administering a dry powder medication dose from the device of claim 9 by applying force on the slide while inhaling on the mouthpiece.
18. A method, comprising administering a dry powder medication dose from the device of claim 10 by applying force on the slide while inhaling on the mouthpiece.
19. A method, comprising administering a dry powder medication dose from the device of claim 11 by applying force on the slide while inhaling on the mouthpiece.
20. A method, comprising administering a dry powder medication dose from the device of claim 12 by applying force on the slide while inhaling on the mouthpiece.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SESE0401453-6 | 2004-06-07 | ||
SE0401453A SE528190C2 (en) | 2004-06-07 | 2004-06-07 | Inhaler |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060021616A1 true US20060021616A1 (en) | 2006-02-02 |
Family
ID=32653550
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/144,832 Expired - Fee Related US7278426B2 (en) | 2004-06-07 | 2005-06-06 | Securing dose quality of an inhalable drug |
US11/144,941 Abandoned US20060021616A1 (en) | 2004-06-07 | 2005-06-06 | Inhaler |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/144,832 Expired - Fee Related US7278426B2 (en) | 2004-06-07 | 2005-06-06 | Securing dose quality of an inhalable drug |
Country Status (14)
Country | Link |
---|---|
US (2) | US7278426B2 (en) |
EP (1) | EP1765439A1 (en) |
JP (1) | JP2008501472A (en) |
KR (1) | KR20070027691A (en) |
CN (2) | CN1964754A (en) |
AU (1) | AU2005251668A1 (en) |
BR (1) | BRPI0511899A (en) |
CA (1) | CA2569336A1 (en) |
IL (1) | IL179488A0 (en) |
MX (1) | MXPA06014264A (en) |
RU (1) | RU2006145656A (en) |
SE (1) | SE528190C2 (en) |
WO (1) | WO2005120615A1 (en) |
ZA (2) | ZA200700133B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180097163A (en) * | 2017-02-22 | 2018-08-30 | 자티슬로 아게 | Box coating apparatus for vacuum coating of substrates, in particular spectacle lenses |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
AU2003220125B2 (en) | 2002-03-20 | 2006-06-15 | Mannkind Corporation | Inhalation apparatus |
SE528190C2 (en) * | 2004-06-07 | 2006-09-19 | Mederio Ag | Inhaler |
ATE486064T1 (en) | 2004-08-20 | 2010-11-15 | Mannkind Corp | CATALYSIS OF DIKETOPIPERAZINE SYNTHESIS |
EP2322180B1 (en) | 2004-08-23 | 2015-05-27 | MannKind Corporation | Diketopiperazine salts for drug delivery |
EP2656836B1 (en) | 2005-09-14 | 2017-07-26 | MannKind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
EP1937341A1 (en) * | 2005-09-28 | 2008-07-02 | Mederio AG | Inhaler device for moisture sensitive drugs and method of operating an inhaler device. |
CN101389348A (en) | 2006-02-22 | 2009-03-18 | 曼金德公司 | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US7806117B2 (en) * | 2006-06-07 | 2010-10-05 | Shin Nippon Biomedical Laboratories, Ltd. | Peroral powder delivery device |
EP2037999B1 (en) | 2006-07-07 | 2016-12-28 | Proteus Digital Health, Inc. | Smart parenteral administration system |
US9125979B2 (en) | 2007-10-25 | 2015-09-08 | Proteus Digital Health, Inc. | Fluid transfer port information system |
US8419638B2 (en) | 2007-11-19 | 2013-04-16 | Proteus Digital Health, Inc. | Body-associated fluid transport structure evaluation devices |
DK2230934T3 (en) | 2007-12-14 | 2012-11-26 | Aerodesigns Inc | Release of aerosolizable food products |
EP2570147B1 (en) | 2008-06-13 | 2017-10-18 | MannKind Corporation | A dry powder inhaler and system for drug delivery |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
RU2470681C2 (en) | 2008-06-20 | 2012-12-27 | Маннкайнд Корпорейшн | Interactive system and method for real-time force profiling in inhalation |
TWI494123B (en) | 2008-08-11 | 2015-08-01 | Mannkind Corp | Ultra-fast use of insulin |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
US8538707B2 (en) | 2009-03-11 | 2013-09-17 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
KR20200028501A (en) | 2009-06-12 | 2020-03-16 | 맨카인드 코포레이션 | Diketopiperazine microparticles with defined specific surface areas |
WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
US8332020B2 (en) | 2010-02-01 | 2012-12-11 | Proteus Digital Health, Inc. | Two-wrist data gathering system |
BR112012019212A2 (en) | 2010-02-01 | 2017-06-13 | Proteus Digital Health Inc | data collection system |
PT105065B (en) * | 2010-04-26 | 2012-07-31 | Hovione Farmaciencia S A | A SIMPLE INHALER OF CAPSULES |
RU2571331C1 (en) | 2010-06-21 | 2015-12-20 | Маннкайнд Корпорейшн | Systems and methods for dry powder drug delivery |
WO2012072542A1 (en) * | 2010-11-29 | 2012-06-07 | Sanofi-Aventis Deutschland Gmbh | Medicated module for an inhaler |
MX353285B (en) | 2011-04-01 | 2018-01-05 | Mannkind Corp | Blister package for pharmaceutical cartridges. |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
US9233159B2 (en) | 2011-10-24 | 2016-01-12 | Mannkind Corporation | Methods and compositions for treating pain |
CN104619369B (en) | 2012-07-12 | 2018-01-30 | 曼金德公司 | Dry-powder medicament induction system and method |
EP2911690A1 (en) | 2012-10-26 | 2015-09-02 | MannKind Corporation | Inhalable influenza vaccine compositions and methods |
KR101445651B1 (en) * | 2013-01-15 | 2014-10-07 | 한국유나이티드제약 주식회사 | Powder Suction Apparatus |
CN105102436B (en) | 2013-03-15 | 2018-06-12 | 曼金德公司 | Crystallite diketopiperazine composition and method |
KR102321339B1 (en) | 2013-07-18 | 2021-11-02 | 맨카인드 코포레이션 | Heat-stable dry powder pharmaceutical compositions and methods |
JP2016530930A (en) | 2013-08-05 | 2016-10-06 | マンカインド コーポレイション | Ventilation device and method |
WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
WO2016181142A1 (en) | 2015-05-12 | 2016-11-17 | Cipla Europe Nv | Inhaler device |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447151A (en) * | 1990-10-04 | 1995-09-05 | Valois | Powder inhaler with suction actuated locking means |
US5507281A (en) * | 1990-08-30 | 1996-04-16 | Boehringer Ingelheim Kg | Device for initiating a mechanical switching operation in synchronism with the breathing |
US6360744B1 (en) * | 2000-09-25 | 2002-03-26 | Microdrug Ag | User interface |
US6422236B1 (en) * | 2000-09-25 | 2002-07-23 | Microdrug Ag | Continuous dry powder inhaler |
US6439227B1 (en) * | 2000-09-25 | 2002-08-27 | Microdrug Ag | Breath-actuation |
US20030150453A1 (en) * | 2001-04-16 | 2003-08-14 | David Edwards | Inhalation device and method |
US20030192538A1 (en) * | 2002-04-12 | 2003-10-16 | Mattias Myrman | Device constituting a powder air-razor |
US6651341B1 (en) * | 2000-09-25 | 2003-11-25 | Microdrug Ag | Foil cutter |
US6668826B1 (en) * | 2000-09-25 | 2003-12-30 | Microdrug Ag | Airbrake |
US6698425B1 (en) * | 1997-02-07 | 2004-03-02 | Astrazeneca Ab | Powder inhaler |
US20040094146A1 (en) * | 2002-09-05 | 2004-05-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Apparatus for the dispensing of liquids, container cartridge suitable for this, and system comprising the apparatus for the dispensing of liquids and the container cartridge |
US20050028813A1 (en) * | 2001-10-05 | 2005-02-10 | Ian Harrison | Apparatus for the nasal or oral delivery of a medicament |
US20050103337A1 (en) * | 2003-10-27 | 2005-05-19 | Anthony James Hickey | Dry powder inhalers, related blister package indexing and opening mechanisms, and associated methods of dispensing dry powder substances |
US20050178382A1 (en) * | 2004-02-09 | 2005-08-18 | Riley William M. | Inhalers with extendable/retractable forward member and associated methods of dispensing inhalant substances |
US20060000473A1 (en) * | 2004-06-07 | 2006-01-05 | Mederio Ag | Securing dose quality of an inhalable drug |
US20060060194A1 (en) * | 2002-10-16 | 2006-03-23 | Roberto Oliva | Single dose inhaler |
US7032593B2 (en) * | 2000-08-14 | 2006-04-25 | Advanced Inhalation Research, Inc. | Inhalation device and method |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1562732A (en) * | 1976-02-10 | 1980-03-12 | Allen & Hanburys Ltd | Device for dispensing medicaments |
US5217004A (en) * | 1990-12-13 | 1993-06-08 | Tenax Corporation | Inhalation actuated dispensing apparatus |
ES2089474T3 (en) | 1991-08-16 | 1996-10-01 | Sandoz Ltd | INHALER FOR THE ADMINISTRATION OF POWDERED SUBSTANCES. |
US5415162A (en) | 1994-01-18 | 1995-05-16 | Glaxo Inc. | Multi-dose dry powder inhalation device |
JP3317823B2 (en) | 1995-08-11 | 2002-08-26 | 株式会社ユニシアジェックス | Dosing device |
IL140312A0 (en) * | 1998-06-22 | 2002-02-10 | Astrazeneca Ab | Device for emptying cavities containing powder by means of suction |
DE10040528A1 (en) * | 2000-08-18 | 2002-02-28 | Pari Gmbh | Inhalation device and method for generating a particle mist for inhalation purposes |
US6941947B2 (en) * | 2002-12-18 | 2005-09-13 | Quadrant Technologies Limited | Unit dose dry powder inhaler |
-
2004
- 2004-06-07 SE SE0401453A patent/SE528190C2/en not_active IP Right Cessation
-
2005
- 2005-05-24 ZA ZA200700133A patent/ZA200700133B/en unknown
- 2005-05-24 AU AU2005251668A patent/AU2005251668A1/en not_active Abandoned
- 2005-05-24 KR KR1020077000391A patent/KR20070027691A/en not_active Withdrawn
- 2005-05-24 MX MXPA06014264A patent/MXPA06014264A/en not_active Application Discontinuation
- 2005-05-24 CN CNA2005800184019A patent/CN1964754A/en active Pending
- 2005-05-24 BR BRPI0511899-9A patent/BRPI0511899A/en not_active IP Right Cessation
- 2005-05-24 RU RU2006145656/14A patent/RU2006145656A/en not_active Application Discontinuation
- 2005-05-24 EP EP05746624A patent/EP1765439A1/en not_active Withdrawn
- 2005-05-24 CA CA002569336A patent/CA2569336A1/en not_active Abandoned
- 2005-05-24 WO PCT/SE2005/000779 patent/WO2005120615A1/en active Application Filing
- 2005-05-24 JP JP2007527127A patent/JP2008501472A/en active Pending
- 2005-06-03 CN CNA2005800184004A patent/CN1997416A/en active Pending
- 2005-06-03 ZA ZA200700132A patent/ZA200700132B/en unknown
- 2005-06-06 US US11/144,832 patent/US7278426B2/en not_active Expired - Fee Related
- 2005-06-06 US US11/144,941 patent/US20060021616A1/en not_active Abandoned
-
2006
- 2006-11-22 IL IL179488A patent/IL179488A0/en unknown
Patent Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5507281A (en) * | 1990-08-30 | 1996-04-16 | Boehringer Ingelheim Kg | Device for initiating a mechanical switching operation in synchronism with the breathing |
US5447151A (en) * | 1990-10-04 | 1995-09-05 | Valois | Powder inhaler with suction actuated locking means |
US6698425B1 (en) * | 1997-02-07 | 2004-03-02 | Astrazeneca Ab | Powder inhaler |
US7032593B2 (en) * | 2000-08-14 | 2006-04-25 | Advanced Inhalation Research, Inc. | Inhalation device and method |
US6668826B1 (en) * | 2000-09-25 | 2003-12-30 | Microdrug Ag | Airbrake |
US6360744B1 (en) * | 2000-09-25 | 2002-03-26 | Microdrug Ag | User interface |
US6651341B1 (en) * | 2000-09-25 | 2003-11-25 | Microdrug Ag | Foil cutter |
US6439227B1 (en) * | 2000-09-25 | 2002-08-27 | Microdrug Ag | Breath-actuation |
US6422236B1 (en) * | 2000-09-25 | 2002-07-23 | Microdrug Ag | Continuous dry powder inhaler |
US20030150453A1 (en) * | 2001-04-16 | 2003-08-14 | David Edwards | Inhalation device and method |
US20050028813A1 (en) * | 2001-10-05 | 2005-02-10 | Ian Harrison | Apparatus for the nasal or oral delivery of a medicament |
US6892727B2 (en) * | 2002-04-12 | 2005-05-17 | Mederio Ag | Device constituting a powder Air-razor |
US20030192538A1 (en) * | 2002-04-12 | 2003-10-16 | Mattias Myrman | Device constituting a powder air-razor |
US20040094146A1 (en) * | 2002-09-05 | 2004-05-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Apparatus for the dispensing of liquids, container cartridge suitable for this, and system comprising the apparatus for the dispensing of liquids and the container cartridge |
US20060060194A1 (en) * | 2002-10-16 | 2006-03-23 | Roberto Oliva | Single dose inhaler |
US20050103337A1 (en) * | 2003-10-27 | 2005-05-19 | Anthony James Hickey | Dry powder inhalers, related blister package indexing and opening mechanisms, and associated methods of dispensing dry powder substances |
US20050178382A1 (en) * | 2004-02-09 | 2005-08-18 | Riley William M. | Inhalers with extendable/retractable forward member and associated methods of dispensing inhalant substances |
US20060000473A1 (en) * | 2004-06-07 | 2006-01-05 | Mederio Ag | Securing dose quality of an inhalable drug |
US7278426B2 (en) * | 2004-06-07 | 2007-10-09 | Mederio Ag | Securing dose quality of an inhalable drug |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180097163A (en) * | 2017-02-22 | 2018-08-30 | 자티슬로 아게 | Box coating apparatus for vacuum coating of substrates, in particular spectacle lenses |
KR102557106B1 (en) | 2017-02-22 | 2023-07-20 | 자티슬로 아게 | Box coating apparatus for vacuum coating of substrates, in particular spectacle lenses |
Also Published As
Publication number | Publication date |
---|---|
ZA200700132B (en) | 2008-04-30 |
CN1997416A (en) | 2007-07-11 |
JP2008501472A (en) | 2008-01-24 |
SE528190C2 (en) | 2006-09-19 |
WO2005120615A1 (en) | 2005-12-22 |
US20060000473A1 (en) | 2006-01-05 |
EP1765439A1 (en) | 2007-03-28 |
RU2006145656A (en) | 2008-07-20 |
CN1964754A (en) | 2007-05-16 |
BRPI0511899A (en) | 2008-01-15 |
US7278426B2 (en) | 2007-10-09 |
IL179488A0 (en) | 2007-05-15 |
KR20070027691A (en) | 2007-03-09 |
SE0401453D0 (en) | 2004-06-07 |
SE0401453L (en) | 2005-12-08 |
CA2569336A1 (en) | 2005-12-22 |
AU2005251668A1 (en) | 2005-12-22 |
ZA200700133B (en) | 2008-05-28 |
MXPA06014264A (en) | 2007-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060021616A1 (en) | Inhaler | |
AU731677B2 (en) | Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament | |
AU749292B2 (en) | Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament | |
JP4921549B2 (en) | Improvement of dry powder inhaler | |
AU2005251670B2 (en) | Securing dose quality of inhalable drug | |
WO2002013897A2 (en) | Inhalation device and method | |
JP2009543658A (en) | Inhalation device and delivery device for administering dry powder medicine | |
US5988163A (en) | Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of delivery of medicament | |
US20050279356A1 (en) | Inhaler using pods | |
JP5394440B2 (en) | Inhaler | |
US20200121870A1 (en) | Low-cost single use powder inhaler | |
US20070068524A1 (en) | Inhaler for moisture sensitive drugs | |
MX2007007393A (en) | A foil cutter in a dry powder inhaler and a method for cutting open a container. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MEDERIO AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MYRMAN, MATTIAS;REEL/FRAME:017096/0254 Effective date: 20050927 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |